Search results
Results from the WOW.Com Content Network
The MDR types most threatening to public health are MDR bacteria that resist multiple antibiotics; other types include MDR viruses, parasites (resistant to multiple antifungal, antiviral, and antiparasitic drugs of a wide chemical variety).
MDR bacteria employ a plurality of adaptations to overcome the environmental insults caused by antibiotics. Bacteria are capable of sharing these resistance factors in a process called horizontal gene transfer where resistant bacteria share genetic information that encodes resistance to the naive population.
Multidrug resistant Gram-negative bacteria (MDRGN bacteria) are a type of Gram-negative bacteria with resistance to multiple antibiotics. They can cause bacteria infections that pose a serious and rapidly emerging threat for hospitalized patients and especially patients in intensive care units . [ 1 ]
Microbes resistant to multiple drugs are termed multidrug-resistant (MDR) and are sometimes called superbugs. [5] Antibiotic resistance, a significant AMR subset, enables bacteria to survive antibiotic treatment, complicating infection management and treatment options. [3]
The evolution of bacteria on a "Mega-Plate" petri dish A list of antibiotic resistant bacteria is provided below. These bacteria have shown antibiotic resistance (or antimicrobial resistance). Gram positive Clostridioides difficile Clostridioides difficile is a nosocomial pathogen that causes diarrheal disease worldwide. Diarrhea caused by C. difficile can be life-threatening. Infections are ...
ESKAPE is an acronym comprising the scientific names of six highly virulent and antibiotic resistant bacterial pathogens including: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. [1] The acronym is sometimes extended to ESKAPEE to include Escherichia coli. [2]
Antibiotic resistance is a growing problem, with increasing rates of multiple drug-resistant tuberculosis (MDR-TB). [1] In 2018, one quarter of the world's population was thought to have a latent infection of TB. [6] New infections occur in about 1% of the population each year. [11]
The Group A drugs are currently levofloxacin or moxifloxacin, bedaquiline and linezolid, therefore XDR-TB is MDR/RR-TB that is resistant to a fluoroquinolone and at least one of bedaquiline or linezolid (or both). In a study of MDR-TB patients from 2005 to 2008 in various countries, 43.7% had resistance to at least one second-line drug. [28]